Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Decitabine + Sapacitabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Decitabine | Dacogen | 5-aza-2-deoxycytidine | DNMT inhibitor (Pan) 5 | Dacogen (decitabine) is cytidine analog that incorporates into DNA and forms covalent bonds with DNA methyltransferases (DNMTs), resulting in decreased DNMT activity and hypomethylation, and potentially leading to reduced tumor growth (PMID: 28159832, PMID: 25130173). Dacogen (decitabine) is FDA approved for use in patients with myelodysplastic syndromes (FDA.gov). |
Sapacitabine | CS-682|CYC682 | Sapacitabine (CS-682) is a nucleoside analog, which interferes with DNA synthesis to induce cell cycle arrest (PMID: 30222471). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01211457 | Phase Ib/II | Sapacitabine + Venetoclax Decitabine + Sapacitabine | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes | Unknown status | USA | 0 |
NCT01303796 | Phase III | Decitabine + Sapacitabine Decitabine | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS) | Completed | USA | SWE | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | BEL | AUT | 0 |